Developer docs
API playgroundTry for free, no card

Search company profiles

Hexal

Full company profile

uuid000n5im

Namestring
Hexal
Legal namestring
Hexal AG
Websiteurl
hexal.de
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Hexal AG is one of the leading pharmaceutical brands in Germany, operating as a wholly-owned brand within the Sandoz generics and biosimilars division (itself spun off from Novartis in October 2023). Founded in 1986 and headquartered in Holzkirchen, Germany, the company employs 5,001-10,000 people and distributes a portfolio of more than 400 products that ranges from over-the-counter (OTC) medications to complex biotechnologically manufactured pharmaceuticals. Therapeutic areas include allergies, thyroid disorders, multiple sclerosis, pain management, growth disorders, osteoporosis, immunology, transplantation medicine, and addiction medicine. Branded OTC franchises include Lorano® and Cetirizin HEXAL® (antihistamines), ACC® (cough remedy), Gingium® (Ginkgo biloba), and MometaHEXAL® (nasal spray).

The business model is built on three pillars: (1) prescription and OTC pharmaceutical product sales through German pharmacies, with prescription revenue determined via statutory health insurer (GKV) discount contracts (Rabattverträge); (2) segment-specific digital engagement via three portals — Patientenportal for patients, Ärzteportal for physicians, and Apothekenportal for pharmacies — plus the FeelinX® patient magazine and continuing medical education programs; and (3) digital health services including the Digitaler MedAntwort Assistent (an AI-powered 24/7 medication information assistant), the Pollenflug mobile app for allergy sufferers, and the GI 4.0® package-insert app. Direct-to-consumer reach runs through these dedicated portals; all physical product distribution runs through licensed German pharmacies, with no direct e-commerce channel.

Hexal's go-to-market is anchored by its brand recognition and its positioning as one of the best-known pharmaceutical brands in German healthcare. The company is the only single-country, domestically focused entity in the dataset — it operates exclusively in Germany — which concentrates exposure to German regulatory and reimbursement dynamics while providing clarity of strategic scope within the broader Sandoz portfolio.

Short descriptiontext

Hexal AG is a Germany-focused generic and OTC pharmaceutical company operating as a brand within Sandoz, distributing more than 400 prescription and OTC products through German pharmacies across allergies, thyroid, MS, pain, and biologics, and supporting patients, physicians, and pharmacists via dedicated online portals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersHolzkirchen, Germany
HQ citystring
Holzkirchen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, over-the-counter medications, biotech generics, pharmacy distribution, patient health education
Industry2 codes
1Generic Finished Dosage Form (FDF) Manufacturing
CodeHLAIABAHPrimaryYes
2Generic Hospital & Institutional Products
CodeHLAIABALPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Hexal generates revenue through the sale of generic and OTC pharmaceutical products across multiple therapeutic areas including allergies, thyroid disorders, multiple sclerosis, pain management, and growth disorders. Products are distributed through pharmacies in Germany with both prescription and over-the-counter offerings.

hexal.de
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1FeelinX®
Description

Patient magazine and companion guide for patients with chronic conditions

hexal.de
+1 more record
Core offering1 text field

Hexal develops, manufactures, and sells over 400 generic and OTC pharmaceutical products in Germany, spanning from over-the-counter remedies to complex biotechnologically manufactured drugs across therapeutic areas including allergies, thyroid disorders, multiple sclerosis, pain, osteoporosis, immunology, transplantation, and growth disorders. The portfolio is complemented by digital health services such as patient, physician, and pharmacy portals, the Digitaler MedAntwort Assistent, the Pollenflug app, and the FeelinX patient magazine. Products are dispensed exclusively through German pharmacies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Hexal – a Sandoz Brand is one of the best-known and strongest brands in German healthcare, offering a broad portfolio of over 400 products spanning from over-the-counter (OTC) medications to highly complex biotechnologically manufactured pharmaceuticals. The product portfolio includes allergy treatments (Lorano®, Cetirizin HEXAL®, MometaHEXAL®), cough remedies (ACC®), neurological/cognitive products (Gingium®), and various other therapeutic areas. In addition to pharmaceutical products, Hexal provides digital health services including the Digitaler MedAntwort Assistent (AI-powered medical question assistant), the Pollenflug App (pollen forecast mobile app), and FeelinX® patient magazine. The company serves patients through dedicated portals (Patientenportal), healthcare professionals through the Ärzteportal, and pharmacists through the Apothekenportal. Various drug delivery devices are offered including the SurePal™ Pen. The portfolio covers therapeutic areas including allergies, thyroid disorders, pain, multiple sclerosis, osteoporosis, immunology, transplantation medicine, and addiction medicine.

Product and service15 records
1ACC® akut 600 mg Hustenlöser Brausetabletten
CategoryOver-the-counter medication
Description

Effervescent tablet cough expectorant (acetylcysteine 600 mg) for treating respiratory conditions, sold as an over-the-counter remedy for German consumers through pharmacies.

2Gingium® 40 mg Filmtabletten
CategoryOver-the-counter medication
Description

Ginkgo biloba-based film-coated tablets (40 mg) sold over the counter for cognitive support and circulation-related indications, distributed to German consumers via pharmacies.

3Lorano®Pro
CategoryOver-the-counter medication
Description

Over-the-counter antihistamine product for the treatment of allergy symptoms, marketed to German consumers and dispensed through pharmacies.

4Cetirizin HEXAL® bei Allergien, 10 mg Filmtabletten
CategoryOver-the-counter medication
Description

Cetirizine-based antihistamine film-coated tablets (10 mg) for allergy relief, sold over the counter in German pharmacies.

5Lorano® akut, 10 mg Tabletten
CategoryOver-the-counter medication
Description

Rapid-acting loratadine-based antihistamine tablets (10 mg) for acute allergy symptom relief, sold as an OTC remedy in German pharmacies.

6Cetirizin HEXAL® Saft bei Allergien, 1 mg/ml Lösung zum Einnehmen
CategoryOver-the-counter medication
Description

Cetirizine-based antihistamine oral solution (1 mg/ml) for allergy treatment, offered as an OTC alternative for consumers preferring liquid formulations.

7MometaHEXAL® Heuschnupfenspray
CategoryOver-the-counter medication
Description

Mometasone nasal spray marketed as an OTC therapy for allergic rhinitis (hay fever) symptoms, sold in German pharmacies.

8SurePal™ Pen
CategoryMedical device
Description

Medical injection pen device for self-administration of Hexal medications (including growth disorder therapies), supporting patient self-injection.

9Digitaler MedAntwort Assistent
CategoryDigital health service
Description

AI-powered assistant providing 24/7 information about Hexal medications in response to medical and pharmaceutical questions, drawing on technical and topic-specific content.

10Pollenflug App (Hexal Pollen App)
CategoryMobile application
Description

Free mobile app providing pollen flight forecasts for 15 plant species up to 7 days in advance, with personalized allergen tracking, symptom diary, and medication logging for allergy sufferers.

11FeelinX® Patientenmagazin
CategoryPatient support program
Description

Patient magazine providing disease education and lifestyle tips for patients with chronic conditions, offered as a companion resource for Hexal medication users.

12Patientenportal
CategoryDigital patient service
Description

Online patient portal providing German consumers with access to health information, product details, and disease management resources for allergies, thyroid disorders, multiple sclerosis, pain, and growth disorders.

13Ärzteportal
CategoryHealthcare professional portal
Description

Online physician portal offering healthcare professionals continuing medical education, scientific updates, case studies, events, and prescribing information across specialties such as immunology, MS, osteoporosis, thyroid, pain, addiction, and transplantation medicine.

14Apothekenportal
CategoryPharmacy portal
Description

Online portal for German pharmacists providing sales support materials, rebate contracts (Rabattverträge), inventory loss compensation, MSV3 services, return management, and digital invoice delivery (Digitaler Belegversand).

15GI 4.0® Beipackzettel-App
CategoryMobile application
Description

Digital package insert app developed by Rote Liste and sponsored by Hexal and 1 A Pharma, providing medication information and package leaflets digitally for German consumers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

1 A Pharma is listed as a sister brand under Hexal's 'Unsere Marken' (Our Brands) section. Both brands operate under the Sandoz umbrella in Germany, with 1 A Pharma representing another generic pharmaceutical brand in the German market alongside Hexal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Parent company of Hexal and one of the world's largest generics and biosimilars companies. Operates globally with a portfolio far broader than Hexal's, but Hexal sits within Sandoz as its flagship German brand.

TypeDirect peer
Description

Major German-headquartered generics and consumer healthcare company with overlapping OTC and generic Rx portfolio. Directly competes with Hexal in German pharmacy channels and discount contracts.

TypeEmerging player
Description

Indian-headquartered global generics manufacturer with growing European and German presence. Competes with Hexal primarily on price in off-patent molecules and through parallel import channels.

TypeDirect peer
Description

Germany's most iconic generics brand, now owned by Teva. Direct competitor to Hexal across prescription generics and OTC in German pharmacies, competing head-to-head for Rabattverträge tenders and pharmacist shelf preference.

TypeDirect peer
Description

German generics specialist (STADA group) operating exclusively through pharmacies with a broad prescription and OTC portfolio. Closely comparable to Hexal in go-to-market model and therapeutic breadth.

TypeEmerging player
Description

Global generics player with an active German subsidiary supplying prescription and OTC products through pharmacies. Partial overlap with Hexal's portfolio and channel model.

TypeDirect peer
Description

German generics manufacturer (Sanofi group) offering prescription and OTC products through pharmacies. Direct overlap with Hexal's generic Rx portfolio and pharmacy-channel strategy.

TypeBroad incumbent
Description

Global generics and biosimilars major (formed from Mylan-Upjohn merger) with strong European footprint. Directly competes with Hexal in German generics tenders and pharmacy distribution.

TypeBroad incumbent
Description

World's largest generic drug manufacturer and owner of Ratiopharm. Competes with Hexal across German and European generic markets, including biosimilars and complex generics.

TypeDirect peer
Description

German pharmaceutical company focused on branded generics and OTC products distributed through pharmacies. Comparable therapeutic area mix and pharmacy-channel distribution model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hexal

Generic Pharmaceuticalshexal.de

Hexal AG is a Germany-focused generic and OTC pharmaceutical company operating as a brand within Sandoz, distributing more than 400 prescription and OTC products through German pharmacies across allergies, thyroid, MS, pain, and biologics, and supporting patients, physicians, and pharmacists via dedicated online portals.

What Hexal does

Hexal AG is one of the leading pharmaceutical brands in Germany, operating as a wholly-owned brand within the Sandoz generics and biosimilars division (itself spun off from Novartis in October 2023). Founded in 1986 and headquartered in Holzkirchen, Germany, the company employs 5,001-10,000 people and distributes a portfolio of more than 400 products that ranges from over-the-counter (OTC) medications to complex biotechnologically manufactured pharmaceuticals. Therapeutic areas include allergies, thyroid disorders, multiple sclerosis, pain management, growth disorders, osteoporosis, immunology, transplantation medicine, and addiction medicine. Branded OTC franchises include Lorano® and Cetirizin HEXAL® (antihistamines), ACC® (cough remedy), Gingium® (Ginkgo biloba), and MometaHEXAL® (nasal spray).

The business model is built on three pillars: (1) prescription and OTC pharmaceutical product sales through German pharmacies, with prescription revenue determined via statutory health insurer (GKV) discount contracts (Rabattverträge); (2) segment-specific digital engagement via three portals — Patientenportal for patients, Ärzteportal for physicians, and Apothekenportal for pharmacies — plus the FeelinX® patient magazine and continuing medical education programs; and (3) digital health services including the Digitaler MedAntwort Assistent (an AI-powered 24/7 medication information assistant), the Pollenflug mobile app for allergy sufferers, and the GI 4.0® package-insert app. Direct-to-consumer reach runs through these dedicated portals; all physical product distribution runs through licensed German pharmacies, with no direct e-commerce channel.

Hexal's go-to-market is anchored by its brand recognition and its positioning as one of the best-known pharmaceutical brands in German healthcare. The company is the only single-country, domestically focused entity in the dataset — it operates exclusively in Germany — which concentrates exposure to German regulatory and reimbursement dynamics while providing clarity of strategic scope within the broader Sandoz portfolio.

Hexal firmographics

Firmographics
Name
Hexal
Legal name
Hexal AG
Website
https://hexal.de
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Hexal AG is a Germany-focused generic and OTC pharmaceutical company operating as a brand within Sandoz, distributing more than 400 prescription and OTC products through German pharmacies across allergies, thyroid, MS, pain, and biologics, and supporting patients, physicians, and pharmacists via dedicated online portals.
Ownership category
akta.pro rank

Hexal industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
akta.pro secondary industry
Generic Hospital & Institutional Products (HLAIABAL)

Keywords

  • Generic pharmaceuticals
  • Over-the-counter medications
  • Biotech generics
  • Pharmacy distribution
  • Patient health education

Where Hexal is headquartered

Location

Headquarters

HQ city
Holzkirchen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Hexal business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Hexal generates revenue through the sale of generic and OTC pharmaceutical products across multiple therapeutic areas including allergies, thyroid disorders, multiple sclerosis, pain management, and growth disorders. Products are distributed through pharmacies in Germany with both prescription and over-the-counter offerings.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Hexal product offering

Product offering

Core offering

Hexal develops, manufactures, and sells over 400 generic and OTC pharmaceutical products in Germany, spanning from over-the-counter remedies to complex biotechnologically manufactured drugs across therapeutic areas including allergies, thyroid disorders, multiple sclerosis, pain, osteoporosis, immunology, transplantation, and growth disorders. The portfolio is complemented by digital health services such as patient, physician, and pharmacy portals, the Digitaler MedAntwort Assistent, the Pollenflug app, and the FeelinX patient magazine. Products are dispensed exclusively through German pharmacies.

Product overview

Hexal – a Sandoz Brand is one of the best-known and strongest brands in German healthcare, offering a broad portfolio of over 400 products spanning from over-the-counter (OTC) medications to highly complex biotechnologically manufactured pharmaceuticals. The product portfolio includes allergy treatments (Lorano®, Cetirizin HEXAL®, MometaHEXAL®), cough remedies (ACC®), neurological/cognitive products (Gingium®), and various other therapeutic areas. In addition to pharmaceutical products, Hexal provides digital health services including the Digitaler MedAntwort Assistent (AI-powered medical question assistant), the Pollenflug App (pollen forecast mobile app), and FeelinX® patient magazine. The company serves patients through dedicated portals (Patientenportal), healthcare professionals through the Ärzteportal, and pharmacists through the Apothekenportal. Various drug delivery devices are offered including the SurePal™ Pen. The portfolio covers therapeutic areas including allergies, thyroid disorders, pain, multiple sclerosis, osteoporosis, immunology, transplantation medicine, and addiction medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • FeelinX®: Patient magazine and companion guide for patients with chronic conditions
  • GI 4.0®

Products and services

  • ACC® akut 600 mg Hustenlöser Brausetabletten Effervescent tablet cough expectorant (acetylcysteine 600 mg) for treating respiratory conditions, sold as an over-the-counter remedy for German consumers through pharmacies.
  • Gingium® 40 mg Filmtabletten Ginkgo biloba-based film-coated tablets (40 mg) sold over the counter for cognitive support and circulation-related indications, distributed to German consumers via pharmacies.
  • Lorano®Pro Over-the-counter antihistamine product for the treatment of allergy symptoms, marketed to German consumers and dispensed through pharmacies.
  • Cetirizin HEXAL® bei Allergien, 10 mg Filmtabletten Cetirizine-based antihistamine film-coated tablets (10 mg) for allergy relief, sold over the counter in German pharmacies.
  • Lorano® akut, 10 mg Tabletten Rapid-acting loratadine-based antihistamine tablets (10 mg) for acute allergy symptom relief, sold as an OTC remedy in German pharmacies.
  • Cetirizin HEXAL® Saft bei Allergien, 1 mg/ml Lösung zum Einnehmen Cetirizine-based antihistamine oral solution (1 mg/ml) for allergy treatment, offered as an OTC alternative for consumers preferring liquid formulations.
  • MometaHEXAL® Heuschnupfenspray Mometasone nasal spray marketed as an OTC therapy for allergic rhinitis (hay fever) symptoms, sold in German pharmacies.
  • SurePal™ Pen Medical injection pen device for self-administration of Hexal medications (including growth disorder therapies), supporting patient self-injection.
  • Digitaler MedAntwort Assistent AI-powered assistant providing 24/7 information about Hexal medications in response to medical and pharmaceutical questions, drawing on technical and topic-specific content.
  • Pollenflug App (Hexal Pollen App) Free mobile app providing pollen flight forecasts for 15 plant species up to 7 days in advance, with personalized allergen tracking, symptom diary, and medication logging for allergy sufferers.
  • FeelinX® Patientenmagazin Patient magazine providing disease education and lifestyle tips for patients with chronic conditions, offered as a companion resource for Hexal medication users.
  • Patientenportal Online patient portal providing German consumers with access to health information, product details, and disease management resources for allergies, thyroid disorders, multiple sclerosis, pain, and growth disorders.
  • Ärzteportal Online physician portal offering healthcare professionals continuing medical education, scientific updates, case studies, events, and prescribing information across specialties such as immunology, MS, osteoporosis, thyroid, pain, addiction, and transplantation medicine.
  • Apothekenportal Online portal for German pharmacists providing sales support materials, rebate contracts (Rabattverträge), inventory loss compensation, MSV3 services, return management, and digital invoice delivery (Digitaler Belegversand).
  • GI 4.0® Beipackzettel-App Digital package insert app developed by Rote Liste and sponsored by Hexal and 1 A Pharma, providing medication information and package leaflets digitally for German consumers.

Companies that use Hexal

Customer profile

Segments3 records

Ideal customer profiles3 records

Hexal technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Hexal partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • 1 A PharmaminorOthers1 A Pharma is listed as a sister brand under Hexal's 'Unsere Marken' (Our Brands) section. Both brands operate under the Sandoz umbrella in Germany, with 1 A Pharma representing another generic pharmaceutical brand in the German market alongside Hexal.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Hexal competitors and assessment

Company assessment

Broad incumbents

  • Sandoz Group: Parent company of Hexal and one of the world's largest generics and biosimilars companies. Operates globally with a portfolio far broader than Hexal's, but Hexal sits within Sandoz as its flagship German brand.
  • Viatris: Global generics and biosimilars major (formed from Mylan-Upjohn merger) with strong European footprint. Directly competes with Hexal in German generics tenders and pharmacy distribution.
  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer and owner of Ratiopharm. Competes with Hexal across German and European generic markets, including biosimilars and complex generics.

Direct peers

  • Stada Arzneimittel: Major German-headquartered generics and consumer healthcare company with overlapping OTC and generic Rx portfolio. Directly competes with Hexal in German pharmacy channels and discount contracts.
  • Ratiopharm (Teva): Germany's most iconic generics brand, now owned by Teva. Direct competitor to Hexal across prescription generics and OTC in German pharmacies, competing head-to-head for Rabattverträge tenders and pharmacist shelf preference.
  • Aliud Pharma: German generics specialist (STADA group) operating exclusively through pharmacies with a broad prescription and OTC portfolio. Closely comparable to Hexal in go-to-market model and therapeutic breadth.
  • Winthrop Arzneimittel: German generics manufacturer (Sanofi group) offering prescription and OTC products through pharmacies. Direct overlap with Hexal's generic Rx portfolio and pharmacy-channel strategy.
  • Dermapharm Holding: German pharmaceutical company focused on branded generics and OTC products distributed through pharmacies. Comparable therapeutic area mix and pharmacy-channel distribution model.

Emerging players

  • Aurobindo Pharma: Indian-headquartered global generics manufacturer with growing European and German presence. Competes with Hexal primarily on price in off-patent molecules and through parallel import channels.
  • Dr. Reddy's Laboratories: Global generics player with an active German subsidiary supplying prescription and OTC products through pharmacies. Partial overlap with Hexal's portfolio and channel model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Hexal social profiles

Digital presence

Hexal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hexal leadership team

Management profile

Number of profiles

Profiles1 record

Hexal funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hexal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hexal

What does Hexal do?

Hexal develops, manufactures, and sells over 400 generic and OTC pharmaceutical products in Germany, spanning from over-the-counter remedies to complex biotechnologically manufactured drugs across therapeutic areas including allergies, thyroid disorders, multiple sclerosis, pain, osteoporosis, immunology, transplantation, and growth disorders. The portfolio is complemented by digital health services such as patient, physician, and pharmacy portals, the Digitaler MedAntwort Assistent, the Pollenflug app, and the FeelinX patient magazine. Products are dispensed exclusively through German pharmacies.

Is Hexal a public or private company?

Hexal is a private company. It is classified as corporate owned and is currently operating.

When was Hexal founded?

Hexal was founded in 1986. It employs 5,001 to 10,000 people.

Where is Hexal based?

Hexal is headquartered in Holzkirchen, Germany, in the Europe region.

How does Hexal make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Hexal's main competitors?

Broad incumbents on record are Sandoz Group, Viatris and Teva Pharmaceutical Industries. Direct peers are Stada Arzneimittel, Ratiopharm (Teva), Aliud Pharma, Winthrop Arzneimittel and Dermapharm Holding. Emerging players are Aurobindo Pharma and Dr. Reddy's Laboratories.

Does Hexal have an API?

No public API is recorded for Hexal.

What industry is Hexal in?

Hexal's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyThe Strüngmann legacy, passed onThe Strüngmann family office launched the Strüngmann Award to recognize European biotech entrepreneurs, with a €100,000 prize. The 2026 winner is Jonathan Talbot of Mosanna and Melodia Therapeutics. The award will expand beyond Germany, Austria, and Switzerland to include more of Europe.Startuprad.io Startup PodcastThe Strüngmann Brothers: Net Worth & the BioNTech Family OfficeThe Strüngmann brothers sold Hexal to Novartis in 2005 for €5.65 billion, then anchored BioNTech with a €136.5–180 million seed in 2008. Their stake peaked at over $50 billion in 2021 and now holds ~43.5% worth ~€10 billion. They plan further BioNTech sales and new bets.PR NewswireGerman Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent LawsuitThe German Federal Supreme Court granted Eli Lilly's appeal in the patent lawsuit against Actavis regarding Alimta's vitamin regimen patent, vacating the prior decision that had denied infringement and returning the case to the Court of Appeal in Dusseldorf for further proceedings. The dispute concerns whether generic competitors' alternative salt forms of pemetrexed would infringe Lilly's patent protection, which remains valid until June 2021. Related infringement proceedings with Hexal AG and ratiopharm GmbH will continue in light of this ruling, with a preliminary injunction against Hexal confirmed in late May 2016.AstrazenecaCourt in Germany finds SEROQUEL XR® formulation patent invalidThe Federal Patent Court in Germany has ruled AstraZeneca's formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets invalid, after it was challenged by Accord Healthcare Limited, Hexal AG, and TEVA Deutschland GmbH. The decision applies only to Germany and is not binding in other jurisdictions, though AstraZeneca faces numerous other SEROQUEL XR®-related patent proceedings globally. The drug generated $82 million in German sales during the ten months ended 31 October 2012, and AstraZeneca has stated it is disappointed with the ruling but remains committed to defending its intellectual property.AstrazenecaUK court finds SEROQUEL XR® formulation patent invalidThe UK High Court ruled on 22 March 2012 that AstraZeneca's formulation patent protecting SEROQUEL XR (quetiapine fumarate prolonged-release tablets) is invalid, marking the first such determination in the UK. The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG, Sandoz, Teva UK, and Teva Pharmaceutical Industries. AstraZeneca expressed disappointment but stated it remains committed to defending its intellectual property, noting a contrasting decision from the Netherlands where the same formulation patent was found valid on 7 March.GlobeNewswireNovartis reports strong results in the first six months of 2005Novartis reported first-half 2005 net sales of $15.1 billion, up 11% year-over-year, and net income of $3.1 billion, up 12%. Pharmaceuticals sales rose 12% to $9.9 billion, driven by Oncology and Cardiovascular growth. The company expects Hexal and Eon Labs acquisitions to have a net negative impact on operating income of $150-250 million.GlobeNewswireNovartis Announces Completion of Hexal AG Acquisition, Integrates Company With SandozNovartis completed its acquisition of German generic drug maker Hexal AG on June 6, integrating it into Sandoz. The combined Sandoz portfolio includes over 600 active ingredients in more than 5,000 dosage forms, employing over 20,000 people. Novartis is seeking US regulatory approval for its separate acquisition of Eon Labs.GlobeNewswireNovartis receives European Commission approval to acquire Hexal AG,Novartis received European Commission approval to acquire German generic drug maker Hexal AG, with completion expected in early June. The deal will integrate Hexal into Sandoz, expanding its portfolio to over 600 active ingredients and 5,000 dosage forms. Sandoz will employ more than 20,000 people after the acquisition.GlobeNewswireNovartis provides update on regulatory developments regarding its pending acquisitions of Hexal AG and Eon LabsNovartis announced submissions to European and US regulators for acquiring Hexal AG and Eon Labs, with a second FTC request extending the waiting period. The tender process for Eon is planned in coordination with regulatory approvals. The press release includes forward-looking statements about the transaction's risks and assumptions.GlobeNewswireNovartis provides update on regulatory developments regarding its pending acquisitions of Hexal AG and Eon LabsNovartis announced submissions to European and US regulators for acquiring Hexal AG and Eon Labs. The US FTC issued a second request, extending the waiting period until 30 days after compliance. The tender process for Eon is planned in coordination with regulatory approvals.